Not that you are being serious, but what we have done at Race is solve the problem that prevents bisantrene being widely used (precipitation in the blood) and worked out how to best use it (cardioprotection and m6A RNA). Both of these discoveries completely changes the value proposition by a couple of orders of magnitude over just bring bisantrene back as a AML salvage drug (i.e. the French approval).
RAC - Charts & Price Action, page-18815
-
- There are more pages in this discussion • 2,785 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
